Purchase this article with an account.
D Sarraf; Photodynamic Therapy of Subretinal Neovascularization Complicating Acquired Juxtafoveal Telangiectasis . Invest. Ophthalmol. Vis. Sci. 2002;43(13):582.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To evaluate the clinical efficacy of photodynamic therapy (PDT) with Verteporfin for the treatment of subretinal neovascular membranes (SRNVM) complicating acquired juxtafoveal telangiectasis. Methods: Observational case series of 3 eyes of 3 diabetic patients receiving standard PDT with Verteporfin (6 mg/m2) to treat subfoveal, classic SRNVM. Snellen visual acuities were recorded and color fundus photographs and fluorescein angiograms were studied pre- and post-PDT for each eye. Results: Each eye received 1 session of PDT with a mean follow-up period of 3 months. Pre-PDT visual acuity ranged from 20/80 to count fingers and was unchanged post-PDT, except for 1 eye that improved from count fingers to 20/400. Enhanced resorption of subretinal fluid and hemorrhage and decreased vascularity and leakage of the membrane upon angiography were noted post-PDT. Collateral damage to the abnormal retinal vasculature associated with the SRNVM was notably absent; associated diabetic retinopathy was improved in 1 eye. Conclusion: Photodynamic therapy may stabilize vision and decrease leakage from SRNVM complicating acquired juxtafoveal telangiectasis. The subfoveal location and the classic angiographic characteristics of these type 2 (subretinal) membranes are ideally suited to PDT which fails to incite collateral retinal vascular damage.
This PDF is available to Subscribers Only